Updates · 20 Sep 2026

Why CHR-P matters

Clinical high risk for psychosis (CHR-P) identifies people with elevated transition risk relative to the general population. It is not a diagnosis of schizophrenia, and it does not mean any individual will inevitably develop psychosis.

Field context, not a product claim. Citations below describe the wider literature. They are not evidence that NWPT-SM32300 prevents psychosis or has established CHR-P efficacy.

Elevated risk is real — and heterogeneous

Meta-analyses of CHR-P cohorts show that cumulative transition rates are higher than in the general population, yet they vary by era, enrichment and care setting. That heterogeneity matters for how trials are designed and how results should be read.

Fusar-Poli et al. (2012) synthesised transition outcomes across high clinical-risk samples.
Salazar de Pablo et al. (2021) updated cumulative transition probabilities over follow-up — again with substantial between-study heterogeneity.

Full citations and DOI links: Evidence library.

Risk is not destiny

Most people identified as CHR-P will not transition within typical follow-up windows. Instruments such as CAARMS (Yung et al., 2005) operationalise research eligibility; they do not equal a lifelong prognosis. Individualised enrichment work (for example Cannon et al., 2016) further shows how expected event rates change with risk profiles — useful for science, not a label for families to fear.

Why earlier intervention research still matters

There is still no broadly approved pharmacotherapy labelled to prevent psychosis in CHR-P across major markets. That gap leaves an open scientific frontier: can carefully designed studies improve symptoms and functioning earlier, and — separately powered — ever answer prevention questions honestly?

Honest limitation. Field unmet need does not imply that any specific candidate (including NWPT-SM32300) works. Programme-specific efficacy and prevention remain not established.

What this means for visitors

CHR-P research is about elevated, variable risk — treat messaging that implies inevitability with scepticism.
Other CBD studies in different populations or products are not NWPT results.
This site does not diagnose, enrol or offer investments.

Evidence library · Science · What this programme aims to establish